Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor used as an active pharmaceutical ingredient in anti-cancer medications. It was the first cancer drug simultaneously approved for two different indications.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 557795-19-4
Sunitinib malate
pharmaceutical raw material
Betahistine hydrochloride
pharmaceutical raw material
1,2,3,4,5,6-Hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one
pharmaceutical raw material
Piretanide
pharmaceutical raw material
Methoxyphenamine hydrochloride
pharmaceutical raw material
(E)-Sunitinib
pharmaceutical raw material
5-((Z)-(5-Fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
pharmaceutical intermediate
3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone
research compound
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WINHZLLDWRZWRT-ATVHPVEESA-N
CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C